Uveal Melanoma (UM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Uveal melanoma (UM) is a rare malignancy that originates from melanocytes within the uveal tract of the eye. Uveal melanoma represents ∼85% of all ocular melanomas, and up to 50% of patients develop metastatic disease. Metastases are most frequently localized to the liver, and few patients are candidates for potentially curative surgery associated with a poor prognosis. Uveal melanoma (UM) has a high tendency to metastasize, resulting in high mortality. The common sites of metastasis include the liver (89%), lung (29%), and bone (17%). UM is adults' most common primary intraocular malignancy, representing 3%–5% of all melanomas. UM most commonly arises from choroidal melanocytes (85%–90%) but can also arise from the iris (3%–5%) and ciliary body (5%–8%).
·
The incidence of uveal melanoma ranges from
5.1 to 6.3 per million population in the USA.
Thelansis’s “Uveal Melanoma (UM)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Uveal
Melanoma (UM) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Uveal Melanoma (UM) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Uveal Melanoma (UM) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment